- Home
- ZTEK vs IKT Comparison
ZTEK vs IKT Comparison
Compare ZTEK & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- IKT
- Stock Information
- Founded
- ZTEK 2008
- IKT 2008
- Country
- ZTEK Canada
- IKT United States
- Employees
- ZTEK N/A
- IKT N/A
- Industry
- ZTEK Major Chemicals
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- IKT Health Care
- Exchange
- ZTEK Nasdaq
- IKT Nasdaq
- Market Cap
- ZTEK 165.9M
- IKT 139.0M
- IPO Year
- ZTEK N/A
- IKT 2020
- Fundamental
- Price
- ZTEK $1.52
- IKT $2.01
- Analyst Decision
- ZTEK
- IKT Buy
- Analyst Count
- ZTEK 0
- IKT 2
- Target Price
- ZTEK N/A
- IKT $8.00
- AVG Volume (30 Days)
- ZTEK 51.2K
- IKT 123.6K
- Earning Date
- ZTEK 06-26-2025
- IKT 05-14-2025
- Dividend Yield
- ZTEK N/A
- IKT N/A
- EPS Growth
- ZTEK N/A
- IKT N/A
- EPS
- ZTEK N/A
- IKT N/A
- Revenue
- ZTEK $44,936.00
- IKT N/A
- Revenue This Year
- ZTEK N/A
- IKT N/A
- Revenue Next Year
- ZTEK N/A
- IKT N/A
- P/E Ratio
- ZTEK N/A
- IKT N/A
- Revenue Growth
- ZTEK 92.38
- IKT N/A
- 52 Week Low
- ZTEK $0.50
- IKT $1.12
- 52 Week High
- ZTEK $1.84
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- ZTEK 51.88
- IKT 49.69
- Support Level
- ZTEK $1.52
- IKT $1.70
- Resistance Level
- ZTEK $1.62
- IKT $2.12
- Average True Range (ATR)
- ZTEK 0.11
- IKT 0.19
- MACD
- ZTEK -0.03
- IKT 0.01
- Stochastic Oscillator
- ZTEK 34.98
- IKT 54.39
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.